ArticleGut and liver2011
Chronic hepatitis C.
Article in Gut and liver, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 54 citations in OpenAlex.
- The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4.African health sciences · 2019Article
- Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.World journal of hepatology · 2017Review
- Hepatitis C Virus Infection in Chronic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2016Review
- Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System.Clinical and vaccine immunology : CVI · 2016Article
- Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C.Archivum immunologiae et therapiae experimentalis · 2016Article
- Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China.SpringerPlus · 2016Article
- A low serum γ-glutamyltransferase level predicts a sustained virological response in patients with chronic hepatitis C genotype 1.Gut and liver · 2014Article
- Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.World journal of gastroenterology · 2013Article
- Lipids and HCV.Seminars in immunopathology · 2013Review
- Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels.World journal of gastroenterology · 2013Article
- Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection.Gut and liver · 2013Article
- Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan.Asian Pacific journal of tropical biomedicine · 2012Article
- Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.The Korean journal of hepatology · 2012Article
- Hepatitis C Infection in Hemodialysis Patients.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment. Major improvements in antiviral therapy for chronic hepatitis C have occurred in the past decade. The addition of ribavirin to interferon-alfa therapy and the introduction of pegylated interferon (PEG-IFN) have substantially improved SVR rates in patients with chronic hepatitis C. The optimization of HCV therapy with PEG-IFN and ribavirin continues to evolve. Studies are ongoing that use viral kinetics to tailor therapy to an individual's antiviral response and determine the ideal length of treatment to maximize the chance of SVR. Improved SVR can be achieved with new specific inhibitors that target the HCV NS3/4A protease and the NS5B polymerase. Several long-term follow-up studies have shown that SVR, when achieved, is associated with a very low risk of virologic relapse. Furthermore, antiviral therapy can reduce the morbidity and mortality rates associated with chronic hepatitis C by reducing fibrosis progression, the incidence of cirrhosis, and hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.